Offer beta lactam monotherapy with piperacillin/tazobactam as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment, unless there are patient-specific or local microbiological contraindications NICE CG151.
Do not offer an aminoglycoside, either as monotherapy or in dual therapy, for the initial empiric treatment of suspected neutropenic sepsis unless there are patient-specific or local microbiological indications NICE CG151.
Do not offer empiric glycopeptide antibiotics to patients with suspected neutropenic sepsis who have central venous access devices unless there are patient-specific or local microbiological indications NICE CG151.
Do not remove central venous access devices as part of the initial empiric management of suspected neutropenic sepsis NICE CG151.